“…The dose of remifentanil was derived from previous studies in both obstetric and non-obstetric patients, and was based on clinical safety and the ability to limit secondary effects. [7][8][9][10][11][12] In previous studies, both Ngan Kee and colleagues and Van de Velde and colleagues showed transient neonatal respiratory compromise lasting up to 5 min with remifentanil bolus in cesarean section under general anesthesia 7, 13 We also observed a significant reduction in Apgar scores in the remifentanil group at 1 and 5 min, with a concomitant difference in umbilical vein pH values, even though these remained in the normal range. These data indicate that, even at low doses, remifentanil has the potential to cause respiratory depression.…”